# Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

> **NCT02795260** · PHASE3 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 1802 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Bacillus Calmette - Guerin
- **BIOLOGICAL:** placebo of Bacillus Calmette - Guerin

## Key facts

- **NCT ID:** NCT02795260
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 1802 (ACTUAL)
- **Last updated:** 2020-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795260, "Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02795260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*